Know Labs

A rendering of the KnowU non-invasive glucose monitor. [Image courtesy of Know Labs]Know Labs (NYSE:KNW) announced interim results highlighting the accuracy of its non-invasive glucose monitoring sensor.

Seattle-based Know Labs conducted a study evaluating its proprietary radiofrequency (RF) dielectric sensor. The sensor non-invasively measured blood glucose in participants with prediabetes and type 2 diabetes. It used venous blood as a comparative reference.

Know Labs reported a mean absolute relative difference (MARD) — a measure of accuracy — of 11.1%. Comparatively, market-leading minimally invasive CGMs from Dexcom and Abbott have demonstrated higher levels of accuracy. Dexcom’s G7 previously demonstrated a MARD of 8.2%, while Abbott’s FreeStyle Libre 3 came in at 7.6%.

However, Know Labs’ non-invasive offering remains an interesting prospect, given there are no FDA-cleared CGMs of this kind at present. Larry Ellingson, a Know Labs board member, …

A rendering of the KnowU non-invasive glucose monitor. [Image courtesy of Know Labs]Know Labs (NYSE:KNW) announced that it entered into a funding agreement for an investment worth up to $12 million.

The Seattle-based company executed a $4 million close as part of this investment with Lind Global Fund II. The Lind Partners, a New York-based institutional fund manager, manages Lind Global Fund II.

Funding helps Know Labs work toward bringing its non-invasive continuous glucose monitoring (CGM) technology to market. The company unveiled KnowU, its wearable CGM set for FDA submission, earlier this week. KnowU’s sensor uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The technology integrates into wearable, mobile or bench-top form factors.

Get the full story at our sister site, Drug Delivery Business News.

A rendering of the KnowU non-invasive glucose monitor. [Image courtesy of Know Labs]Know Labs (NYSE:KNW) today unveiled KnowU, its wearable, non-invasive continuous glucose monitor (CGM) system.

Seattle-based Know Labs first announced its initial prototype last June. It says KnowU is the result of an accelerated development process over the past eight months. The system incorporates the sensor developed by the company that it plans to submit for FDA clearance.

Know Labs tested its proprietary sensor technology in a lab setting and incorporated it into the prototype for stability outside the lab. Now, it offers the sensor in what it considers a miniaturized and wearable form. That sensor utilizes the company’s proprietary Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The technology integrates into wearable, mobile or bench-top form factors.…

The Gen 1 prototype device. [Image courtesy of Know Labs]Know Labs (NYSE:KNW) announced today that it priced an underwritten public offering worth about $7 million in proceeds.

Seattle-based Know Labs, which develops a non-invasive glucose monitor, is offering 28 million shares of common stock. It priced the offering at 25¢ per share, with aggregate gross proceeds expected to total $7 million.

The company expects the offering to close on or about Sept. 29, subject to customary closing conditions. Know Labs also granted underwriters a 30-day option to purchase up to 4.2 million additional shares of common stock. Those shares cover over-allotments at the 25¢ per share public offering price.

Get the full story at our sister site, Drug Delivery Business News.

The Gen 1 prototype device. [Image courtesy of Know Labs]Know Labs (NYSE:KNW) today announced results from a new study that further demonstrate the accuracy of its Bio-RFID sensor technology.

Last month, the company unveiled the prototype for its proprietary non-invasive sensor technology. Its proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The Know Labs technology integrates into wearable, mobile or bench-top form factors.

Seattle-based Know Labs’ study showed that continued algorithm refinement and more high-quality data improved the sensor’s accuracy.

Get the full story at our sister site, Drug Delivery Business News.

The Gen 1 prototype device. [Image courtesy of Know Labs]Know Labs (NYSE:KNW) today unveiled the first-generation prototype of its non-invasive glucose monitoring technology.

Seattle-based Know Labs incorporated its Bio-RFID sensor into the first generation of this technology. The proprietary Bio-RFID technology uses spectroscopy to direct electromagnetic energy through a substance or material. Through this, it can capture a unique molecular signature. The Know Labs technology integrates into wearable, mobile or bench-top form factors.

This non-invasive technology demonstrated technical feasibility and stability in blood glucose measurements in a lab environment. Now, the company revealed this technology incorporated in a portable device.

According to Know Labs, no medical-grade, commercially available non-invasive means of measuring blood glucose exist currently. The company hopes to deliver the first FDA-cleared non-invasive blood glucose monitor for thos…

[Image from Know Labs]Know Labs (NYSE:KNW) today announced the results of a feasibility study comparing its glucose monitoring technology to the Dexcom G6 CGM.

The company titled its study “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6.” It’s presenting results today at the American Association of Clinical Endocrinology (AACE) Annual Meeting in Seattle.

Know Labs conducted a series of internal studies between December 2022 and February 2023. The company sought to validate the technical feasibility of its Bio-RFID sensor technology for quantifying blood glucose concentration (BGC). Its studies evaluated five healthy participants using the Dexcom G6 as a reference device.

Get the full story at our sister site, Drug Delivery Business News.

[Image from Know Labs]Know Labs (NYSE:KNW) announced that it entered into a series of strategic partnerships as it looks to move toward a major regulatory nod.

Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top form factors. Know Labs developed the first application of Bio-RFID as a non-invasive glucose monitor.

Get the full story at our sister site, Drug Delivery Business News.

[Image from Know Labs]Know Labs (NYSE:KNW) announced today that it received a new patent equating its diagnostic technology to the current glucose monitoring standard.

Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. It integrate into wearable, mobile or bench-top form factors. The first application of the technology comes in the form of a non-invasive glucose monitor.

The company’s new patent equates the technology to mean absolute relative difference, or MARD. This standard, used by diabetes researchers and glucose meter makers, establishes a range of clinical accuracy. Know Labs said the patent expands its IP portfolio to nearly 90 patents issued and pending.

Get the full story at our sister site, Drug Delivery Business News.